Sign up United Kingdom
Proactive Investors - Run By Investors For Investors
Why invest in SCLP?
Scancell Holdings Plc: THE INVESTMENT CASE

Scancell Holdings part of the new cancer revolution

The AIM-listed drug developer is at the vanguard of advances in the emerging field of immuno-oncology
scientist with vial
The company's innovations have shown some early promise - particularly SCIB-1, which has been used with some success to treat melanoma

The fight against cancer has moved into a new phase as drugs are developed that use the body’s immune system to tackle the killer disease.

And AIM-listed Scancell Holdings Plc (LON:SCLP) is at the vanguard of advances in the emerging field of immuno-oncology and is working on two technologies that are showing early promise.

In May, investors got behind the business, backing a placing and open offer of new shares that brought in £8.7mln before expenses.

Bankrolling development 

That cash will fund early clinical trials of a drug generated using its Moditope platform as well as supporting the development of its more advanced assets.

They are SCIB-1 and SCIB-2, which target and stimulate existing cells that make up the body’s defence mechanisms.

At the turn of the year, Scancell reported the “compelling” results of Phase I/II melanoma trial of SCIB-1, and the immunotherapy has continued to impress since. Another trial of SCIB-1, this time in combination with another type of drug called a checkpoint inhibitor, is set to kick off later this year. 

Similarly, last December, Cancer Research UK agreed to fund and sponsor a Phase I/II lung cancer clinical study of its SCIB-2 vaccine, also in combination with a checkpoint inhibitor.

Lung cancer is a killer

Lung cancer remains one of the most difficult cancers to treat and accounts for more than a quarter of all cancer deaths.

That’s more than breast, prostate and colon cancers combined. Around 228,000 people receive a lung cancer diagnosis in the US alone and more than 160,000 will not survive.

A read-out from the combination study is due in the first half of next year.

ImmunoBody and Moditope 

Both SCIB-1 and SCIB-2 emerged from Scancell’s patented ImmunoBody platform.

MODI-1 is its first drug using the company’s Moditope technology. Initially, it will be deployed in the clinic to treat breast and ovarian cancers as well as sarcoma (tumours found in fat, muscle, bone and tendons). That study is expected to begin in 2019.

MODI-1 acts to stimulate the production of killer CD4+ T cells that seek out and kill tumour cells that would otherwise be hidden from the immune system.  

Partnership renewed

Scientists at the Karolinska Institute, led by Professors Lars Klareskog and Vivianne Malmström, uncovered an essential role for citrullinated proteins, which are normally associated with arthritis, in this process.

Back in August, the company extended its collaboration with the rheumatology department of the Swedish medical research university.

The share price, which has fluctuated between 10-16p in the past year, appears to have found a level recently at around 12p.

At that price, the company is worth just shy of £50mln. Whether this is a fair valuation of the business is open to interpretation.

Hard to value

Normally, you would carry out discounted cash flow analysis to assess just what Scancell’s assets are worth.

But as Hardman, the City research house pointed out in a recent note, the company’s innovations are at too early stages to be subjected to this sort of analysis.

Instead, it’s probably worth looking at the trends within the industry and the deals being done.

Last year, there were 35 transactions in the oncology sector in excess of US$1bn, according to EvalutePharma,

Of that total, 32 were focused on immuno-oncology. In other words, this is a particularly active (and potentially rewarding) area of R&D.

As Hardman analyst Martin Hall said in his note: “Scancell’s proprietary technologies are in the ‘hot’ area of immuno-oncology and targeting markets of significant unmet medical need.

“Recent deals have demonstrated the price that big pharma is willing to pay for validated assets in the field.”


Following May's fundraising, Scancell has £10.3mln of cash in the bank at the end of April (Apr 2017: £2.7mln).

The company posted a loss for the year to April of £4.3mln (2017: loss of £3.5mln).

“It has been a strong period for Scancell as we continue to make significant progress with our pipeline of cancer immunotherapies,” said chief executive Cliff Holloway.

“We have expanded our product opportunities through in-licensing and external collaborations, including with Cancer Research UK and BioNTech, who have provided further validation of our ImmunoBody and Moditope platforms.”

He added: “The fundraisings this financial year have given us the necessary funds to progress our ImmunoBody platform pipeline and to continue to advance Modi-1 towards the clinic.

“SCIB1 has demonstrated impressive survival data to date, and operational and regulatory activities are underway for the initiation of the international SCIB1 checkpoint inhibitor combination Phase 2 study in patients with melanoma.”

View full SCLP profile View Profile

Scancell Holdings Plc Timeline

Related Articles

car-t cells definition
September 24 2018
The phase I clinical study will evaluate the safety of MaxCyte's MCY-M11 chimeric antigen receptor in people with relapsed or difficult-to-treat ovarian cancer and peritoneal mesothelioma
September 20 2018
Following the disappointment of its DMD treatment over summer, Summit is leveraging its Discuva platform to develop new antibiotics, which doctors are in desperate need of
Picture of growing facility
May 07 2018
Establishing a vertically integrated business model provides THC with the ability to optimise efficiencies in the manufacturing process.

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

© Proactive Investors 2018

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use